Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

The global Phase III clinical study of JHL1149 in patients with non-small cell lung cancer (NSCLC)

Trial Profile

The global Phase III clinical study of JHL1149 in patients with non-small cell lung cancer (NSCLC)

Status: Planning
Phase of Trial: Phase III

Latest Information Update: 29 Mar 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bevacizumab (Primary)
  • Indications Non-small cell lung cancer
  • Focus Registrational; Therapeutic Use
  • Sponsors Eden Biologics

Most Recent Events

  • 16 Oct 2018 National Medical Products Administration of the PRC (NMPA) has approved Phase I and Phase III Clinical Trial Application for JHL1149.
  • 23 Aug 2018 New trial record
  • 09 Aug 2018 According to a JHL Biotech media release, the EMA confirmed it agrees with JHL's development approach, clinical development proposal and design of this phase 3 study. Based on the EMA's review of these factors, the results of the Phase III clinical study will be acceptable for the submission of a Marketing Authorization Application as a biosimilar product, assuming the Phase III trial is completed successfully.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top